Trapped Between Full Capacity and Commodity Pricing
Q1 delivered revenue growth of 4.9% but PAT collapsed 27.3% quarter-on-quarter. Management's feed-cost headwind was worse than prior guidance implied, with 2-3 months of margin pressure ahead and zero room for volume growth.
On the headline, SKM's Q1 FY-2027 tells a story of modest resilience: revenue up 4.9% year-on-year to ₹184.3 crore, PAT up 46.5% to ₹23.8 crore. Then you look at the quarter-on-quarter numbers and the real story emerges—revenue flat (-1.3%) and PAT down 27.3%—and you realize the company is not in growth mode. It is in a margin trap, squeezed between full capacity utilization and commodity pricing with no way out for the next 2-3 quarters.
The Tension: Growth Stalled, Margins Crashing
₹184.3 Cr
+4.9% | on prior guidance
-1.3%
Full capacity = demand ceiling hit
+46.5%
Low prior base; misleading
-27.3%
Margin collapse from soya costs
The year-on-year gains are misleading. PAT jumped 46.5% but off a depressed prior quarter—the real signal is the 27.3% quarter-on-quarter collapse, driven by soya cost inflation that management now admits will persist for 2-3 months minimum. Net profit margin compressed to 12.4% (down from ~16% implied prior), operating margin to 16.9%, and neither has any near-term relief mechanism. Management made explicit on the call: they have zero cost-pass mechanism with customers ('pricing is not dependent on our cost…it is driven by market prices'). The realization improvement to ₹770/kg—up ₹48 versus ₹722 prior—came entirely from rupee depreciation, not pricing power or operational excellence.
Management's Claims vs. What Holds Up
Full capacity utilization; modest growth FY27
Revenue +4.9% YoY, -1.3% QoQ on stated full capacity
Supported
Feed cost is biggest margin pressure; 2-3 months minimum headwind
PAT -27.3% QoQ, NPM 12.4%; no month-by-month roadmap provided
Supported, magnitude vague
Realization improved to ₹770/kg
Improvement credited to 'primarily exchange rate (₹ depreciation)', not pricing or volume mix
Partially overstated
No pricing power; prices market-driven, cost cannot be passed
MD: 'any increase in cost cannot be transferred…pricing not dependent on our cost'
Supported; structural weakness
Easy sheds (5% cost reduction) online by Nov-Dec 2026
4 complete; rest by Nov-Dec 2026 (4 months away, aggressive timeline)
On track but execution-dependent
What Changed This Quarter
Feed cost inflation materialized worse than prior guidance; soya 'substantial increase'
Capacity constraint confirmed real (not transient); QoQ revenue flat on full utilization
Japan office approval delayed Jun-Jul → Aug-Sep 2026; no new customers won yet
Branded eggs (SKM Best acquisition) active; ₹40-50 Cr revenue added this FY
Branded EBITDA margins explicitly lower than core egg powder business
How the Street Is Positioned
The stock opened at ₹273.5 on result day (Jul 29) and fell 8.63% on the day-1 reaction—a sharp repricing that the market read as justified. The selloff reflects belief that the margin collapse from feed costs was worse than prior guidance had signaled, the relief timeline (2-3 months) is vague, and the company has confirmed it has zero pricing power to recover costs.
₹249.85
Day 1 down -8.63%
₹371.6
-32.76% drawdown
₹143.1–₹371.6
+74.6% off low
10.3
Oversold, but not a buy signal
The stock is well below its 20-day and 50-day moving averages but above the 200-day, limiting technical support. More telling: FII ownership has collapsed to 0.49% (down 0.27pp QoQ from 0.76%), while DII ownership remains minimal at 0.36%. Bulk deals show some nibbling at ₹231–₹232 (NK Securities, Alphagrep, Junomoneta rotating in), but earlier selling at ₹190–₹199 (SILVERLEAF, BACHA GOUTHAM) suggests institutional rotation out, not conviction. The thin institutional ownership and post-result selling confirm that the margin deterioration is being treated as genuine, not a one-quarter blip.
The Bull Case vs. The Bear Case
Ranked Risks (by how much they should concern a holder)
Feed cost inflation (soya, uncontrollable) extends beyond 2-3 months
HighZero cost-pass mechanism with customers. Any extension of soya costs will keep PAT depressed. Q1 already showed -27.3% QoQ damage; Q2 will test whether the relief timeline holds.
Zero pricing power in international commodity markets
HighManagement explicitly: cannot transfer costs to buyers. Growth must come from volume (capex, FY28+) or market price recovery (uncontrollable). Structural vulnerability.
Capacity fully utilized; zero volume growth until capex (FY28+)
HighQoQ revenue -1.3% despite full capacity confirms demand ceiling hit. No volume upside for 18+ months. Growth must be price-led, but international prices are 'quite stable' (management's words).
Execution delays on easy sheds and capex timeline
MediumEasy sheds Nov-Dec 2026 completion is 4 months away (aggressive). Japan office already delayed Jun-Jul → Aug-Sep. Biogas still in test/commercialization phase (Sept 2026 target unproven).
Branded eggs margin dilution
MediumSKM Best acquisition adds ₹40-50 Cr revenue but at lower EBITDA margins than core egg powder. Revenue grows; PAT per rupee of revenue declines. Margin recovery deferred to FY28+.
What to Watch Next
1 · Q2 QoQ PAT (September 2026 result)
The litmus test for feed cost relief. Management says 2-3 months minimum headwind. If Q2 PAT remains down >15% QoQ, the relief timeline is slipping. If it improves ≥10% QoQ, margin recovery thesis holds. This single number makes or breaks confidence in guidance.
2 · Easy sheds full completion and 5% cost reduction realized (Nov-Dec 2026)
Management committed to 5% overall production cost savings once all sheds are online. Q4 results will show whether that translates to 50-80 bps OPM recovery. If delayed or underwhelming, capex and execution credibility take a hit.
3 · Capex board approval and branded business plan (Oct 2026–Mar 2027)
₹400 Cr capex board approval by October; branded eggs business plan finalized by March 2027. These reset the multi-year narrative. However, without Q2-Q3 margin recovery, the market is unlikely to re-rate on forward expectations.
The Single Number to Track
From Q2 FY-2027 onwards, watch quarterly PAT sequentially. The margin compression in Q1 (-27.3% QoQ) was attributed to feed costs with a stated 2-3 month relief window. If Q2 QoQ PAT improves, the thesis holds and you can look past near-term pain to the capex story. If Q2 PAT stays flat or worsens, the feed cost timeline is slipping and the margin trap deepens. EPS will follow, but the PAT trend is the earliest signal of whether guidance is tracking.
SKM is not a broken story, but it is a trapped one. Full capacity, commodity pricing, and zero pricing power create a structural squeeze for the next 2-3 quarters. The ₹400 crore capex plan and branded eggs diversification are credible long-term bets, but they arrive in FY28-29 at the earliest. The margin profile of the latter is dilutive near-term. Management is pragmatic and transparent about these constraints (they don't hide the 'no cost-pass' reality), but transparency doesn't change the math.
The day-1 selloff of 8.63% was justified. The oversold RSI of 10.3 hints at reversal opportunity only if catalysts (easy sheds, feed cost relief, capex approval) deliver on schedule in the months ahead. Until then, the stock is a hold-and-watch, not a buy-the-dip. The narrative shifts when Q2 PAT trends north; until it does, the trap remains real.
Informational and educational content only. Not investment advice.